HKr18 Activators
HKr18 Activators encompass a diverse range of chemical compounds designed to indirectly enhance the functional activity of HKr18 through various signaling pathways. Forskolin, IBMX, and Epigallocatechin gallate, through their respective actions on adenylate cyclase and kinase inhibition, elevate cAMP levels and reduce inhibitory kinase activity, which primes protein kinase A (PKA) to phosphorylate target proteins, potentially including HKr18 or its associated factors, thus amplifying its function. Phorbol 12-myristate 13-acetate and PMA act as activators of protein kinase C (PKC), which may influence HKr18 through phosphorylation events. LY294002 and Sphingosine-1-phosphate modulate PI3K and sphingosine receptor signaling, respectively, which can indirectly increase HKr18 activity by altering intracellular kinase activation dynamics or by reducing negative regulatory influences on HKr18.
Further enhancement of HKr18 activity is achieved by compounds such as Thapsigargin and A23187, which elevate intracellular calcium levels, thereby activating calcium-dependent signaling pathways that can influence the functional state of HKr18 through calmodulin-dependent kinases or other calciumresponsive proteins. Staurosporine, despite its broad kinase inhibition spectrum, may preferentially relieve HKr18 from specific kinase-mediated repression, enhancing its activity. Similarly, U0126 and SB203580, by inhibiting MEK and p38 MAPK, respectively, shift signaling equilibria to favor pathways that activate HKr18, potentially by releasing HKr18 from negative feedback or competitive interaction with the MAPK pathway. Collectively, these activators orchestrate a multifaceted enhancement of HKr18, utilizing distinct but interconnected signaling events to amplify its activity without directly increasing its expression or requiring direct binding to the protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased levels of cAMP, which can enhance the activity of HKr18 by activating protein kinase A (PKA). PKA then phosphorylates target proteins that may include HKr18 or its associated factors, thus enhancing its functional activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP, leading to their accumulation. This can indirectly enhance HKr18 activity by maintaining PKA activation and sustaining phosphorylation events that promote HKr18 function. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate substrates involved in signaling cascades related to HKr18 activity, potentially enhancing its functional role in the cell. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
As a kinase inhibitor, epigallocatechin gallate could selectively inhibit kinases that negatively regulate HKr18, thus removing inhibitory phosphorylation and enhancing HKr18 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that could alter downstream AKT signaling. By inhibiting negative regulatory pathways of HKr18, this compound may indirectly enhance HKr18 function. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate engages with its receptors to activate signaling pathways that could converge on enhancing HKr18 activity through intracellular kinase activation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin increases intracellular calcium levels, which can activate calcium-dependent signaling pathways, potentially leading to the enhancement of HKr18 activity through calmodulin-dependent kinases or other calcium-sensitive proteins. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Although staurosporine is a broad-spectrum kinase inhibitor, it may lead to the selective activation of HKr18-related pathways by inhibiting kinases that exert negative control over HKr18 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that may shift signaling dynamics to favor the activation of pathways involving HKr18, as the inhibition of MEK could reduce competitive signaling through the MAPK pathway. | ||||||